Please use this identifier to cite or link to this item:
|Title:||Evolving role of tumor antigens for future melanoma therapies.||Austin Authors:||Andrews, Miles C;Woods, Katherine;Cebon, Jonathan S ;Behren, Andreas||Affiliation:||Ludwig Institute for Cancer Research, Austin Health, Heidelberg, Victoria, Australia
Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
|Issue Date:||1-Jun-2014||Publication information:||Future Oncology (london, England); 10(8): 1457-68||Abstract:||Human tumor rejection antigens recognized by T lymphocytes were first defined in the early 1990s and the identification of shared tumor-restricted antigens sparked hopes for the development of a therapeutic vaccination to treat cancer, including melanoma. Despite decades of intense preclinical and clinical research, the success of anticancer vaccines based on these antigens has been limited. While melanoma is a highly immunogenic tumor, the ability to prime immunity with vaccines has not generally translated into objective disease regression. However, with the development of small molecules targeting oncogenic proteins, such as V600-mutated BRAF, and immune checkpoint inhibitors with demonstrable long-lasting clinical benefit, new opportunities for antigen-targeted directed therapies are emerging.||Gov't Doc #:||25052755||URI:||http://ahro.austin.org.au/austinjspui/handle/1/12314||DOI:||10.2217/fon.14.84||URL:||https://pubmed.ncbi.nlm.nih.gov/25052755||Type:||Journal Article||Subjects:||checkpoint inhibitors
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 5, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.